GB2094301A - Improvements in or relating to organic compounds - Google Patents
Improvements in or relating to organic compounds Download PDFInfo
- Publication number
- GB2094301A GB2094301A GB8205882A GB8205882A GB2094301A GB 2094301 A GB2094301 A GB 2094301A GB 8205882 A GB8205882 A GB 8205882A GB 8205882 A GB8205882 A GB 8205882A GB 2094301 A GB2094301 A GB 2094301A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compound
- formula
- free acid
- compounds
- acid form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
Abstract
Compounds of formulae Ia-Ig, <IMAGE> their production and use as pharmaceuticals.n
Description
SPECIFICATION
Improvements in or relating to organic compounds
The present invention relates to leukotriene analogues, their production use, and pharmaceutical preparations containing same.
According to the invention there are provided compounds which, in free acid form, are of formulae la-lg,
in which R, in free acid form, is
wherein (C) R1 is NHCH2COOH
and R2 is
or (D) R, is NHCH2COOH
and R2 is H,
or (E) R1 is OH
and R2 is H.
It will be appreciated that, of the above compounds, those of formulae la and Ib, Ic and Id and le and If are enantiomeric pairs, differing from each other in their chirality at Cs and C6. The compounds of formulae la, Ic, le (and Ig) have the chirality 5R, 6S and the compounds of formula Ib, Id and If have the chirality 5S, 6R.
The compounds of formulae la and Ib have the double bond configuration 7E, 9Z, 11 E, 1 4Z.
The compounds of formulae Ic and Id have the double bond configuration 7E, 9Z, 11Z, 14Z.
The compounds of formulae le and If have the double bond configuration 8Z, 1 OZ, 1 2E, 1 4Z and the compounds of formulae Ig have the double bond configuration 7E, 9E, liE, i4Z.
In the above formulae, the compounds, for convenience, are shown in free acid form. They exist also in lactone, salt and ester forms, which forms are also embraced by the present invention. When in lactone form, their partial formulae, as will be appreciated, are as follows
Of the salt forms, the pharmaceutically acceptable salt forms are preferred and as examples may be given the alkali and alkaline earth metal salt forms as well as ammonium and amine salt forms, the sodium and potassium salt forms being particularly preferred.
Of the ester forms, the pharmaceutically acceptable ester forms are preferred and as examples may be given the alkyl, silyl, cycloalkyl, cycloalkyl-alkyl and aralkyl, the C1 -4 alkyl esters being preferred .
Since the compounds of the invention contain two or three carboxylic acid functions, depending on the significance of R1 and R2, so called partial salts and partial esters, i.e.
compounds in which not all the carboxylic acid functions are in salt or ester form, are possible.
The invention also provides a process for the production of the compounds of the invention, which process comprises
(a) obtaining a compound which, in free acid form, is of formula la or Ib, above, by reacting a compound which, in free acid form, is of formula II,
with a compound of formula III,
in which R1 and R2 are as defined above, optionally in protected form,
(b) obtaining a compound which, in free acid form, is of formula Ic or Id, above, by reacting a compound which, in free acid form, is of formula IV
with a compound of formula (Ill), above, optionally in protected form
(c) obtaining a compound which, in free acid form, is of formula Ig, above, by reacting a compound which, in free acid form, is or formula V,
with a compound of formula III, above, optionally in protected form, or (d) obtaining a compound which, in free acid form, is of formula le or If, above, by double bond rearrangement (1,7 hydride shift) of a compound which, in free acid form, is of formula Ic or Id, the above reactions being followed, where required, by removal of any protecting group(s) and, where desired, by isolation of the resulting compounds in free acid, lactone, salt or ester form and, where desired, by separation of the enantiomeric 5R,6S and 5S, 6R pairs.
The above reactions a) to c) are suitably carried out in the presence of a strong base (pKa > 12) such as a trialkylamine, e.g. triethylamine, and in an inert polar solvent such as in an alkanol, e.g. methanol. A suitable reaction temperature is from 1 0, to 50"C, preferably room temperature. Reaction times are generally of the order of from 1 5 minutes to 3 to 4 hours. In the above reactions it is preferred for the compound of formulae II, IV and V to be employed in ester form, particularly in C1 -4 alkyl ester form and especially in the methyl ester form.
The 1,7 hydride shift involved in the double bond rearrangement d) is temperature and time dependent, occuring already at room temperature when compounds of formula Ic and Id are dissolved in a solvent, and progressing with lapse of time. At higher temperatures the rearrangement is accelerated. It will, therefore, be appreciated that when carrying out reaction b), and it is desired to obtain a high yield of compounds of formula Ic or Id, it is preferred to employ relatively low reaction temperatures and/or relatively short reaction times. On the other hand, where it is desired to obtain compounds of formula le or If, reactions b) and d) can effectively be combined by employing, in reaction b), relatively high reaction temperatures and/or relatively long reaction times, in situ double bond rearrangement d) then occuring to yield compounds of formula le or If.
The above reactions a) to c) employ a racemic E epoxide and, accordingly, the products resulting comprise mixtures of both the 5R,6S and 5s,6R enantiomers. Where it is desired to separate the pair, this may be carried out in conventional manner. Where, however, in the compounds of the invention, R, and R2 have the significances (C), above, a preferred method is the use of reverse phase HPLC on the compounds in free acid form. Where, however, R, and R2 have the significances (D) or (E), above, the separation is preferably carried out using conventional HPLC methods on the compounds when in ester form.
It will be appreciated that the radical R, in the compounds of the invention, contains at least one optically active centre (two when r, and R2 have significance (C)). It is not intended that the present invention be limited to any particular isomeric form of compounds arising from such centre(s).
Interconversion as between the various forms of the compounds of the invention, e.g. salt, free acid, lactone and ester forms may be carried out in conventional manner. For example, ester forms can be converted into salt forms by treatment with the appropriate aqueous dilute base at a pH of from 9 to 10. The salt forms can be converted to the free acid forms by aqueous acidification. The free acid forms can be converted to the lactone forms by acid treatment at a pH of iess than 5, and the salt or acid form can be converted to ester forms by base or acid catalysed esterification using an appropriate alcohol.
The compounds of formulae 11, III, IV and V used in the process of the invention are either known or may be obtained in conventional manner from available starting materials. The compound of formula ill, wheren R1 and R2 have the significance (D), above, is preferably employed in protected form, it being particularly preferable to use N-trifluoroacetylcysteinylglycine methyl ester. Deprotection in the final compound can be carried out in conventional manner, e.g. by base hydrolysis.
Representative compounds of the invention are as foilows a) representative of the compounds of formula la:- 5(R)-Hydroxy-6(S)-S-giutathionyl-7E,9Z, 11 E, 1 4Z-eicosatetraenoic acid,
5(R)-Hydroxy-ô(S)-S-cysteinyigRycinyl-7 E, 9Z, 11 E, 1 4Z-eicosatetraenoic acid and 5(R)-Hydroxy-6(S)-S-cysteinyl-7E,9Z, 11 E, 1 4Z-eicosatetraenoic acid; b) representative of the compounds of formula Ib: 5(S)-Hydroxy-6(1R)-S-glutathionyl-7E,9Z, 11 E, 1 4Z-eicosatetraenoic acid,
5(S)-Hydroxy-6(R)-S-cysteinylglycinyl-7 E, 9Z, 11 E, 1 4Z-eicosatetraenoic acid and 5(S)-Hydroxy-ô(R)-S-cysteinyl-7 E, 9Z, 11 E, 1 4Z-eicosatetraenoic acid; c) representative of the compounds of formula ic:- 5(R)-Hydroxy-6(S)-S-glutathionyl-7 E, 9,11 , 1 1,14Z-eicosatetraenoic acid, 5(R)-Hydrnxy-6(S)-S-cysteinylglycinyl-7 E, 9,11 , 1 4Z-eicosatetraenoic acid and
5(R)-Hydroxy-6(S)-S-cysteínyl-7E,9,1 1,15Z-eicosatetraenoic acid; d) representative of the compounds of formula Id: 5(S)-Hydroxy-6(R)-S-glutathionyl-7E,9,1 1,14Z, eicosatetraenoic acid, 5(S)-Hydrnxy-6(R)-S-cysteinyIglycinyl7 E, 9,11 , 1 1,14Z-eicosatetraenoic acid and 5(S)-Hydroxy-6(R)-S-cysteinyl-7 E, 9,11 , 1 1,14Z-eicosatetraenoic acid; e) representative of the compounds of formula le: 5(R)-Hydrnxy-6(S)-S-glutathionyl-8, 1 OZ, 1 2E, 1 4Z-eicosatetraenoic acid,
5(R)-Hydroxy-6(S)-S-cysteinylglycinyl-8, 1 OZ, 1 2E, 1 4Z-eicosatetraenoic acid 5(R)-Hydroxy.6(S)-S-cysteinyl-8, 1 OZ, 1 2E, 1 4Z-eicosatetraenoic acid; f) representative of the compounds of formula If: 5(S)-Hydroxy-6(R)-S-glutathionyl-8, 1 OZ, 1 2E, 1 4Z-eicosatetraenoic acid,
5(S)-Hydrnxy-6(R)-S-cysteinylglycinyl-8, 1 OZ, 1 2E, 1 4Z-eicosatetraenoic acid and 5(S)-Hydroxy-6(R)-S-cysteinyl-8, 1 OZ, 1 2E, 1 4Z-eicosatetraenoic acid; g) representative of the compounds of formula ig: 5(R)-Hydroxy-6(S)-S-giutathionyl-7,9, 1 E, 1 4Z-eicosatetraenoic acid,
5(R).Hydroxy-6(S)-S-cysteinylglycinyl-7,9, ii E, 1 4Z-eicosatetraenoic acid,
5(R)-Hydroxy-6(S)-S-cysteinyl-7,9, ii E, 1 4Z-eicosatetraenoic acid.
The compounds of the present invention are pharmacologically active, being SRS-A partial agonists/antagonists as indicated by tests in vitro on guinea pig ileum segments at concentra tions of from 0.1 ng to 1 yg according to the method of Schild 1947 Brit. J. Pharm. 2 197206 and the in vivo Guinea Pig Pulmonary Function Test of Austen and Drazen 1 974 J. Clin.
Invest 53: 1679-1685 at dosage of from 0. 1 iug/kg to 0.1 mg/Kg. The compounds are accordingly indicated for therapeutic use in the treatment of allergic/anti-inflammatory reactions of the pulmonary system where SRS-A is thought to be a causal mediator, i.e. in allergic lung disorders such as extrinsic asthma and industrial asthmas such as Farmers lung and Pigeon
Fanciers Lung, bronchitis and cystic fibrosis, as well as in other disorders involving SRS-A as casual mediator, such as allergic skin diseases, ectopic and atopic eczemas, contact hypersensitivity and angioneurotic oedema.Compounds of the invention are also indicated for use in the treatment of hypertensive or hypotensive conditions as shown by their effect on systemic blood pressure in unconscious rats, according to the test described in Pharmacological Experiments on
Intact Preparations, University of Edinburgh (1 970)63.
The compounds may be administered by various routes. Thus, they may be administered by the oral and rectal routes, topically and parenterally e.g. by injection, being usually employed in the form of a pharmaceutical composition. Such compositions form part of the present invention and are prepared in a manner well known in the pharmaceutical art and normally comprise at least one compound of the invention in association with a pharmaceutically-acceptable carrier therefor. In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient.Thus the composition can be in the form of tablets, lozenges, sachets, cachets, elixirs, suspensions, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, injection suspensions and sterile packaged powders.
Some examples of suitable carriers are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyland propyl-hydroxybenzoate, talc, magnesium stearate or mineral oil. The compositions of the invention may, as is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
Preferably the compositions are formulated in a unit dosage form, each dosage containing from 5yg to 10 mg, more usually 10 y9 to 1 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and animals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.
The active compounds are effective over a wide dosage range and for example dosages per day will normally fall within the range of 5,ug to 10 mg in the treatment of adult humans, more usually in the range of from 10 g to 1 mg. However it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered and the chosen route of administration and therefore the above ranges are not intended to limit scope of the invention in any way.
The following Examples illustrate the invention.
EXAMPLE 1.
5(R)-Hydroxy-6(S).S-cysteinylglycinyl- 7E, 9Z, 11 E, I 4Z-eicosatetraenoic acid and 5(S)-Hydroxy-6(R)-S-cysteinylglycinyl- 7E, 9Z, t E, 1 4Z-eicosatetraenoic acid (compounds of formulae la and lb, respectively) N-trifluoroacetylcysteinylglycine methyl ester (1.44 mg) (Tet. Lett. 21, 3143, (1980)) was dissolved in dry methanol (50 yI) and triethylamine (1.0 mg) added. This solution was then added to methyl E 5,6 oxido-7E,9Z,11E,14Z-eicosatetraenoate (0.8 mg) Tet. Lett. 21, 4123, (1980)) and the resultant solution allowed to stand at room temperature form 3 hours.The 5R, 6S and 5S, 6R isomers of the dimethyl N-trifluoroacetyl derivatives of the title compounds so formed were then separated by high pressure chromatography using a column packed with S5NH Spherisorb silica eluted with dichlormethane plus 0.5% methanol. The isomers eluted in the order 5R, 6S first 5S, 6R second, both compounds being colourless oils, A max. 269,278 and 291 nm.
The isomers were separately hydrolysed at room temperature overnight using 3 parts aqueous 0.1 M potassium carbonate solution to 1 part methanol. The title compounds were then further purified by high pressure chromatography using a column packed with 5y C18 Nucleosil reverse phase silica eluted with methanol: water 70:30, the pH being adjusted to 5.2 with acetic acid.
EXAMPLE 2.
5(RJ-Hydroxy-6(SJ-S-cysteinylglycinyl 7E, 9, 11, 1 4Z-eicosatetraenoic acid and 5(SJ-Hydroxy-6(RJ-S-cysteinylglycinyl 7E,9, 11,14Z-eicosatetraenoic acid (compounds of formulae
Ic and Id, respectively)
The title compounds were prepared from methyl E 5,6 oxido-7E,9,1 1,14Z eicosatetraenoate (Tet. Lett 21, 4123, (1980)) using the procedure given in Example 1;A max. 271, 281 and 291 nm.
EXAMPLE 3.
5(RJ-Hydroxy-6(SJ-S-cysteinylglycinyl 7,911 E, 1 4Z-eicosatetraenoic acid
The title compound was prepared from methyl E 5,6 oxidek-7,9.1 1 E,14-eicosatetraenoate (Tet. Lett. 21, 3143 (1980)) using the procedure given in Example 1, above; Amax 276, 277 and 287 nm.
EXAMPLE 4.
5(RJ-Hydroxy-6(SJ-S-cysteinylglycinyl 8, 1 OZ, 1 2E, 1 4Z-eicosatetraenoic acid and 5(S)-Hydroxy-6(R)-S-cysteinylglycinyl 8, 1 OZ, 1 2E, 1 4Z-eicosatetraenoic acid (compounds of formulae le and If, respectively).
The title compounds were obtained as minor products when applying the procedure described in Example 2. They were both isolated as colourless oils, Amex. 281, 293, 306 and 322 nm, using the reverse phase high pressure chromatography system described in Example 1.
EXAMPLE 5.
5(R)-Hydroxy-6(S)-S-glutathionyl-7E, 9Z, 11 E, 14Z-eicosatetraenoic acid and 5(SJ-Hydroxy-6(RJ-S-glutathionyl-7E,9Z, 11 E, 1 4Z-eicosatetraenoic acid (compounds of formula la and Ib, respectively).
Triethylamine (6.06 mg ) was added to glutathione (4.6 mg) and the mixture dissolved in dry methanol (50 iLl). This solution was then added to methyl E 5,6 oxido-7E,9Z,11 E,14Zeicosatetraenoate (1.66 mg) Tet. Lett. 21, 4123, (1980)) and the resultant solution allowed to stand at room temperature for 3 hours. The reaction mixture was then evaporated to dryness to give methyl 5(RS)-Hydroxy-6(SR)-S-glutathionyl-7E,9Z, 11 E, 1 4Z-eicosatetraenoate was redissolved in 3 parts aqueous 0.1 M potassium carbonate solution to 1 part methanol and the resultant clear solution allowed to stand at room temperature overnight.The title compounds were then separated using high pressure chromatography using a column packed with 5y C1s Nucleosil reverse phase silica eluted with methanol/water (60:40) adjusted to a pH of 4.2 with acetic acid. The order of elution using this system is first 5R, 6S isomer, second 5S,6R isomer, both with A max. 269, 278 and 291 nm.
EXAMPLE 6.
5(R)-Hydroxy-6(S)-S-glutathíonyl-7E, 9, 11, 1 4Z-eicosatetraenoic acid and 5(S)-Hydroxy-6(R)-S-glutathionyl- 7E, 9, 11, 1 4Z-eicosatetraenoic acid (compounds of formulae Ic and Id, respectively).
The title compounds were prepared from methyl E 5,6 oxido-7E,9, 11 , 1 4Z-eicosatetraenoate (Tet. Lett. 21, 4123(1980)) using the procedure given in Example 5; A max. 271, 281, and 291 nm.
EXAMPLE 7.
5(P)-Hydroxy-6(S)-S-glutaThionyl-l 9, 11 E, 14Z-eicosatetraenoic acid (compound of formula Ig)
The title compound was prepared from methyl E 5,6 oxido-7,9,1 1 E,14Z-eicosatetraenoate (Tet. Lett. 21, 3143 (1980)) using the proceedure given in example 5; A max. 267, 277 and 287 nm.
EXAMPLE 8.
5(R)-Hydroxy-6(S)-S-cysteinyl 7E, 9Z, 11 E, 1 4Z-eicosatetraenoic acid and 5(S)-Hydroxy-6(R)-S-cysteinyl- 7E, 9Z, 11 E, 1 4Z-eicosatetraenoic acid (compounds of formulae la and Ib, respectively)
N-trifluoroacetylcysteine methyl ester (1.23 mg) was dissolved in dry methanol (50 yI) and triethylamine (1.0 mg) added. This solution was then added to methyl E 5,6 oxido-7E,9Z,1 1- E, 1 4Z-eicosatetraenoate (0.8 mg) (Tet. Lett. 21, 4123, (1980)) and the resultant solution allowed to stand at room temperature for 20 minutes. The 5R,6S and 5S,6R isomers of the dimethyl N-trifluoroacetyl derivatives of the title compounds so formed were then separated by high pressure chromatography using a column packed with S5NH Spherisorb (registered Trade
Mark) eluted with Hexane: dichloromethane: methanol 75:25:1. The isomers were isolated as colourless oil; A max. 269, 278 and 291 nm.
The isomers were separately hydrolyzed at room temperature overnight using 3 parts aqueous 0.1 m potassium carbonate solution to 1 part methanol. The title compounds were then further purified by high pressure chromatography using a column packed with 5y C18Nucleosil reverse phase silica eluted with methanol: water 70:30, the pH being adjusted to 5.2 with acetic acid.
EXAMPLE 9.
5(RJ-Hydroxy-6(S)-S-cysteinyl- 7E, 9, 11, 1 4Z-eicosatetraenoic acid and 5(S)-Hydroxy-6(R)-S-cysteinyl- 7E, 9, 11, 1 4Z-eicosatetraenoic acid (compounds of formulae Ic and
Id, respectively)
The title compounds were prepared from methyl E 5,6 oxido-7E,9, 11 , 1 4Z-eicosatetraenoate (Tet. Lett. 21, 4123 (1980)) using the procedure given in Example 8; A max. 271, 281 and 291 nm.
EXAMPLE 10.
5(R)-Hydroxy-6(S)-S-cysteinyl-7,9, 11 E, 1 4Z-eicosatetraenoic acid (compound of formula Ig)
The title compound was prepared from methyl E 5,6 oxido-7,9, 11 E, 1 4Z eicosatetraenoate (Tet. Lett. 21 3143 (1980)) using the procedure given in Example 8; A max. 267, 277 and 287 nm.
EXAMPLE 11.
5(R)-Hydroxy-6(S)-S-glutathioyl 8, 1 OZ, 1 2E, 1 4Z-eicosatetraenoic acid and 5(S)-Hydroxy-6(R)-glutathionyl 8, 1 OZ, 12E, 14Z-eicosatetraenoic acid (compounds of formulae le and If, respectively)
The title compounds were obtained as minor products when applying the procedure described in Example 6. They were both isolated as colourless oils, A max. 281, 293, 306 and 322 nm, using the reverse phase high pressure chromatography system described in Example 5.
Claims (11)
1. A compound which, in free acid form, is of one of the formulae la-lg.
in which R, in free acid form, is
wherein (C) R, is NHCH2COOH
and R2 is
or (d) R, is NHCH2CO0H and R2 is H,
or (E) R, is OH
and R2 is H.
2. A compound of claim 1 in free acid form.
3. A compound of claim 1 in lactone form.
4. A compound of claim 1 in ester form.
5. A compound of claim 4 in pharmaceutically acceptable ester form.
6. A compound of claim 1 in salt form.
7. A compound of claim 6 in pharmaceutically acceptable salt form.
8. A compound of claim 1 as identified in any one of the foregoing Examples.
9. A process for the production of a compound of claim 1 which comprises:
(a) obtaining a compound which, in free acid form, is of formula la or Ib, above, by reacting a compound which, in free acid form, is of formula II,
with a compound of formula Ill,
in which R, and R2 are as defined above, optionally in protected form,
(b) obtaining a compound which, in free acid form, is of formula Ic or Id, above, by reacting a compound which, in free acid form, is of formula IV
with a compound of formula (III), above, optionally in protected form
(c) obtaining a compound which in free acid form, is of formula lg, above, by reacting a compound which, in free acid form, is of formula V,
with a compound of formula Ill, above, optionally in protected form, or (d) obtaining a compound which, in free acid form, is of formula le or If, above, by double bond rearrangement (1,7 hydride shift) of a compound which, in free acid form, is of formula Ic or Id, the above reactions being followed, where required, by removal of any protecting group(s) and, where desired, by isolation of the resulting compounds in free acid, lactone, salt or ester form and, where desired, by separation of the enantiomeric 5R,6S and 5S, 6R pairs.
1 0. A process of claim 9 substantially as hereinbefore described with reference to any one of the foregoing Examples.
11. A pharmaceutical composition comprising a compound of claim 1 in free acid, lactone or pharmaceutically acceptable salt or ester form, in association with a pharmaceutically acceptable diluent or carrier.
1 2. A compound of claim 1 for use in the treatment of allergic/inflammatory disorders involving SRS-A as casual mediator.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8205882A GB2094301B (en) | 1981-03-03 | 1982-03-01 | Improvements in or relating to organic compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8106695 | 1981-03-03 | ||
| GB8205882A GB2094301B (en) | 1981-03-03 | 1982-03-01 | Improvements in or relating to organic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB2094301A true GB2094301A (en) | 1982-09-15 |
| GB2094301B GB2094301B (en) | 1985-02-06 |
Family
ID=26278630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8205882A Expired GB2094301B (en) | 1981-03-03 | 1982-03-01 | Improvements in or relating to organic compounds |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2094301B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4609744A (en) * | 1983-04-21 | 1986-09-02 | Merck Frosst Canada Inc. | 4-oxo-benzopyran carboxylic acids |
| EP0206741A2 (en) | 1985-06-18 | 1986-12-30 | Merck Frosst Canada Inc. | Leukotriene antagonists |
| US4758594A (en) * | 1984-07-18 | 1988-07-19 | Schering Corporation | Inhibitors of slow reacting substance of anaphylaxis |
| US4798842A (en) * | 1984-07-18 | 1989-01-17 | Schering Corporation | Inhibitors of slow reacting substance of anaphylaxis |
| US4889873A (en) * | 1984-07-18 | 1989-12-26 | Schering Corporation | Inhibitors of slow reacting substance of anaphylaxis |
| US4988716A (en) * | 1984-07-18 | 1991-01-29 | Schering Corporation | Inhibitors of slow reacting substance of anaphylaxis |
| US4990526A (en) * | 1985-06-18 | 1991-02-05 | Merck Frosst Canada, Inc. | Leukotriene antagonists, compositions and methods of use thereof |
| US5017583A (en) * | 1983-04-21 | 1991-05-21 | Merck Frosst Canada, Inc. | Leukotriene antagonists |
-
1982
- 1982-03-01 GB GB8205882A patent/GB2094301B/en not_active Expired
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4609744A (en) * | 1983-04-21 | 1986-09-02 | Merck Frosst Canada Inc. | 4-oxo-benzopyran carboxylic acids |
| US5017583A (en) * | 1983-04-21 | 1991-05-21 | Merck Frosst Canada, Inc. | Leukotriene antagonists |
| US4758594A (en) * | 1984-07-18 | 1988-07-19 | Schering Corporation | Inhibitors of slow reacting substance of anaphylaxis |
| US4798842A (en) * | 1984-07-18 | 1989-01-17 | Schering Corporation | Inhibitors of slow reacting substance of anaphylaxis |
| US4889873A (en) * | 1984-07-18 | 1989-12-26 | Schering Corporation | Inhibitors of slow reacting substance of anaphylaxis |
| US4988716A (en) * | 1984-07-18 | 1991-01-29 | Schering Corporation | Inhibitors of slow reacting substance of anaphylaxis |
| EP0206741A2 (en) | 1985-06-18 | 1986-12-30 | Merck Frosst Canada Inc. | Leukotriene antagonists |
| US4990526A (en) * | 1985-06-18 | 1991-02-05 | Merck Frosst Canada, Inc. | Leukotriene antagonists, compositions and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2094301B (en) | 1985-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0201823B1 (en) | Novel intermediates for the production of pharmaceuticals | |
| EP0068739B1 (en) | Sulphur-containing 5-hydroxy-alkanoic acid derivatives, their use as pharmaceutical preparations and process for their production | |
| US5256689A (en) | Cholesterol lowering compounds | |
| DE2902442A1 (en) | 9-DEOXY-9A-METHYLENE ISOSTERS OF PGI LOW 2, THE METHOD OF MANUFACTURING THEM AND THE PHARMACEUTICAL AND VETERINAL MEDICINAL PRODUCTS CONTAINING THEM | |
| GB2094301A (en) | Improvements in or relating to organic compounds | |
| US3896166A (en) | Formyl-substituted tyrosine | |
| JPH02745A (en) | New hmg-coa reductase inhibitor | |
| HU187466B (en) | Process for producing new 5-cyano-prostacycline derivatives and pharmaceutical compositions containing them | |
| EP0063858B1 (en) | Leukotriene analogues, their preparation and use in pharmaceutical compositions | |
| HU201941B (en) | Process for producing 7-oxabicycloheptane aminoalcohol | |
| US4783480A (en) | 6-keto-prostaglandin E1 derivatives | |
| FR2577927A1 (en) | PROSTAGLANDIN-SUBSTITUTED 7-OXABICYCLOHEPTANE ANALOGUES WITH THERAPEUTIC PROPERTIES | |
| US4886885A (en) | Compound containing tetrazolyl groups and their use for treating allergies and cardiovascular disease | |
| FI72973C (en) | Process for the preparation of pharmacologically active 2-oxabicyclo / 3.3.0 / octane derivatives. | |
| US4968711A (en) | Tetrazole compounds and use as anti-allergics | |
| US4410526A (en) | Oxazolidin-2-one prostaglandin compounds | |
| US4739113A (en) | Bis(cyclopropanecarboxamido)alkadienedioic acids as renal dipeptidase inhibitors | |
| US4588713A (en) | Selective biologically active 7-oxo-prostacyclin derivatives and pharmaceutical compositions containing same | |
| HU180589B (en) | Process for producing dihydronicotinic acid derivatives | |
| HU206342B (en) | Process for producing 6-oxo-prostaglandine derivatives and pharmaceutical compositions containing them as active components | |
| GB2177401A (en) | Novel organic compounds and their use as intermediates in the production of pharmaceuticals | |
| US4372973A (en) | 16-Amino-postaglandin derivatives, their acid addition salts, and a process for the preparation thereof | |
| US4532138A (en) | Thiazolidin-2-one analogs | |
| KR790001979B1 (en) | Process for the preparation of cyclopentane derivatives | |
| JPS6225667B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |